Immune tolerance induction using Fc-fusion-protein recombinant factor IX in severe haemophilia B
Haemophilia
.
2021 Nov;27(6):e776-e779.
doi: 10.1111/hae.14424.
Epub 2021 Oct 2.
Authors
Ali Amid
1
2
,
Heather Perkins
1
,
Julie Gauthier
3
4
,
Arnaud Bonnefoy
4
5
,
Manuel Carcao
6
7
,
Georges-Étienne Rivard
4
5
,
Robert J Klaassen
1
2
Affiliations
1
Division of Hematology/Oncology, Children's Hospital of Eastern Ontario (CHEO), Ottawa, Ontario, Canada.
2
Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
3
Molecular Diagnostic Laboratory, CHU Sainte-Justine, Montreal, Québec, Canada.
4
Department of Pediatrics, Université de Montréal, Montreal, Québec, Canada.
5
Division of Hematology/Oncology, Montreal, Québec, Canada.
6
Division of Haematology/Oncology, Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.
7
Department of Paediatrics, University of Toronto, Ontario, Canada.
PMID:
34599780
DOI:
10.1111/hae.14424
No abstract available
Publication types
Letter
MeSH terms
Factor IX
Factor VIII
Hemophilia A* / drug therapy
Hemophilia B* / drug therapy
Humans
Immune Tolerance
Recombinant Fusion Proteins
Substances
Recombinant Fusion Proteins
Factor VIII
Factor IX